| Business Summary | | Genomic
Solutions
Inc.
designs,
develops,
manufactures,
markets
and
sells
genomic
and
proteomic
instrumentation,
software,
consumables
and
services.
Unlike
many
other
life
sciences
companies
in
the
DNA
microarray
and
proteomic
markets,
the
Company
offers
integrated
systems
with
demonstrated
market
acceptance.
The
Company's
DNA
microarray
and
proteomic
products
and
systems
enable
researchers
to
perform
complex,
high-volume
experiments
at
lower
costs
and
in
less
time
than
with
traditional
techniques.
Customers
use
the
Company's
integrated
and
automated
systems
to
produce
microarrays,
maintain
DNA
libraries,
quantify
gene
expression
levels
and
isolate,
identify
and
characterize
proteins,
thereby
facilitating
more
rapid
and
less
expensive
drug
discovery.
The
Company
sells
its
products
to
pharmaceutical
and
biotechnology
companies,
government
agencies,
universities
and
private
research
institutions. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | GNSL
designs,
develops,
manufactures,
markets
and
sells
instruments,
software,
consumables
and
services
used
to
determine
the
activity
level
of
genes
and
to
isolate,
identify
and
characterize
proteins.
For
the
six
months
ended
6/01,
total
revenues
rose
4%
to
$8.8
million.
Net
loss
applicable
to
Common
before
extraordinary
item
fell
31%
to
$8.7
million.
Revenues
reflect
higher
sales
of
consumables
and
services.
Net
loss
reflects
a
lower
deemed
dividend. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Robert Shepler, 44 Chairman | -- | -- | Jeffrey Williams, 35 Pres,
CEO, Director | $517K | $1.4M | Steven Richvalsky, 39 CFO,
Exec. VP, Treasurer | 270K | 728K | Gary Kendra, 39 Exec.
VP, Sec., Gen. Counsel | -- | -- | Michael Kurek, Ph.D., 53 Exec.
VP of Sales and Service | 214K | 357K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|